Last updated: September 1, 2026
Omega-3-carboxylic acids, commercialized as Epanova by AstraZeneca, reached the U.S. market as a prescription treatment for severe hypertriglyceridemia but failed to establish a durable commercial position. AstraZeneca acquired Omthera Pharmaceuticals for up to $443 million in 2013, obtained FDA approval for Epanova in 2014, and later discontinued development after the STRENGTH cardiovascular outcomes trial failed to show benefit. The product had limited disclosed revenue, no demonstrated cardiovascular-outcomes advantage, and faced competition from Vascepa, Lovaza, generic omega-3 products, and inexpensive dietary supplements.
The principal commercial conclusion is that omega-3-carboxylic acids are a discontinued or commercially inactive branded asset rather than a growing pharmaceutical franchise. Patent protection remains relevant for freedom-to-operate analysis, but regulatory, clinical, and market factors have reduced the practical value of the estate.
What are omega-3-carboxylic acids and how does Epanova work?
Omega-3-carboxylic acids are free fatty acid forms of marine-derived omega-3 molecules, principally eicosapentaenoic acid and docosahexaenoic acid. Epanova used these free fatty acids rather than the ethyl ester forms used in Lovaza and several generic products.
The free fatty acid formulation was designed to improve absorption, particularly in patients with lower-fat diets. Its approved U.S. indication was adjunctive treatment of severe hypertriglyceridemia, generally defined as triglyceride levels of at least 500 mg/dL. The FDA label stated that the effect of Epanova on cardiovascular morbidity and mortality had not been established [1].
Epanova’s clinical positioning depended on three potential advantages:
- Absorption that was less dependent on dietary fat.
- Reduction in triglyceride levels in severe hypertriglyceridemia.
- Potential differentiation from omega-3 ethyl ester products.
The third proposition failed in the most commercially important setting. The STRENGTH trial did not demonstrate cardiovascular benefit.
When did Epanova receive FDA approval and lose commercial momentum?
The key regulatory and commercial milestones are as follows.
| Date |
Event |
Commercial relevance |
| May 2013 |
AstraZeneca agreed to acquire Omthera |
Entry into omega-3 cardiovascular and lipid assets |
| May 2014 |
FDA approved Epanova |
Approval for severe hypertriglyceridemia |
| 2014-2019 |
Epanova marketed in the United States |
Limited uptake relative to established omega-3 products |
| 2019 |
AstraZeneca initiated the STRENGTH cardiovascular outcomes study |
Attempt to establish differentiation from triglyceride-lowering competitors |
| January 2020 |
AstraZeneca discontinued Epanova development in certain markets |
Commercial and clinical reassessment |
| November 2020 |
STRENGTH trial stopped for futility |
No demonstrated reduction in major adverse cardiovascular events |
| 2021 onward |
Epanova ceased to be an active strategic growth product |
Franchise value shifted from commercial expansion to residual regulatory and IP value |
AstraZeneca acquired Omthera for approximately $323 million in upfront consideration, with potential milestone payments of approximately $120 million [2]. The transaction also included Omthera’s lead product and its omega-3 development platform.
The acquisition price was paid before Epanova had generated meaningful commercial proof. The subsequent failure of STRENGTH eliminated the principal pathway for a broader cardiovascular indication.
How large is the omega-3 prescription market?
The omega-3 prescription market is fragmented and highly price-sensitive. Products compete across four categories:
- Prescription EPA-only products, led by Vascepa.
- Prescription omega-3 ethyl ester products, including Lovaza and generics.
- Omega-3 carboxylic acid products, principally Epanova.
- Over-the-counter fish-oil and nutritional supplements.
The market has been shaped by a split between triglyceride reduction and cardiovascular-risk reduction. Triglyceride lowering alone has not consistently translated into cardiovascular benefit. Vascepa gained commercial strength after the REDUCE-IT trial demonstrated cardiovascular-risk reduction in a defined high-risk population, although the trial used purified icosapent ethyl rather than a mixed EPA/DHA product [3].
Epanova’s mixed EPA/DHA composition placed it at a disadvantage against Vascepa in cardiovascular-risk discussions. DHA-containing products can also increase low-density lipoprotein cholesterol in some patients, creating a potential prescribing concern in mixed dyslipidemia.
How does Epanova compare with Vascepa and Lovaza?
| Attribute |
Epanova |
Vascepa |
Lovaza |
| Active ingredient |
Omega-3 free fatty acids, mainly EPA and DHA |
Icosapent ethyl, purified EPA ethyl ester |
Omega-3-acid ethyl esters, EPA and DHA |
| FDA indication |
Severe hypertriglyceridemia |
Severe hypertriglyceridemia; cardiovascular-risk reduction in eligible patients |
Severe hypertriglyceridemia |
| Cardiovascular outcomes evidence |
STRENGTH failed |
REDUCE-IT positive |
No comparable outcomes claim |
| Formulation rationale |
Free fatty acid absorption |
Purified EPA |
Ethyl ester formulation |
| Commercial status |
Development and promotion discontinued |
Active branded franchise |
Brand and generic competition |
| Main market risk |
Clinical differentiation and limited demand |
Generic erosion and label-specific competition |
Price erosion and substitution |
Vascepa’s outcomes evidence created the strongest commercial differentiation in the category. Lovaza and generic omega-3-acid ethyl esters retained a role in triglyceride lowering but faced substantial price competition.
What caused the financial decline of omega-3-carboxylic acids?
Epanova’s financial trajectory was driven by acquisition cost, weak product uptake, expensive outcomes development, and the absence of a broader approved label.
AstraZeneca did not report Epanova as a major standalone revenue contributor in its public financial reporting. The company grouped products into broader cardiovascular and metabolic categories, which prevents a reliable product-level sales series from public annual reports. The available financial record supports the following assessment:
- Acquisition consideration: approximately $323 million upfront.
- Maximum reported transaction value: approximately $443 million including milestones.
- Product revenue: not separately disclosed at a material level.
- Development cost: substantial, because STRENGTH enrolled more than 13,000 patients across a large international outcomes program.
- Terminal event: discontinuation after futility analysis.
- Residual value: limited to remaining regulatory rights, patents, know-how, and potential licensing or reformulation opportunities.
The economic model required Epanova to move beyond a narrow severe-hypertriglyceridemia indication. That expansion depended on positive cardiovascular-outcomes data. Once STRENGTH failed, the expected addressable market narrowed to a commodity-like triglyceride-lowering segment.
What did the STRENGTH trial show?
STRENGTH was a randomized cardiovascular outcomes trial evaluating omega-3 carboxylic acids against corn oil in patients with dyslipidemia and high cardiovascular risk. It enrolled more than 13,000 participants.
The study was terminated early after an interim analysis showed a low probability of demonstrating benefit. The trial did not show a statistically significant reduction in the composite cardiovascular endpoint [4].
This result had four immediate commercial effects:
- It removed the basis for a cardiovascular-risk-reduction claim.
- It weakened the rationale for premium pricing.
- It reduced the value of the free-fatty-acid delivery platform.
- It made additional large outcomes trials economically unattractive.
The result also reinforced a broader market distinction: triglyceride reduction is a pharmacodynamic effect, while cardiovascular-risk reduction requires separate clinical evidence.
What patents protect omega-3-carboxylic acids?
The Epanova patent estate was directed mainly to pharmaceutical compositions containing omega-3 free fatty acids, methods of treatment, and formulation characteristics. The core U.S. patent family originated with Omthera and was later controlled by AstraZeneca.
Public patent records identify Omthera-related U.S. patents in the following general categories:
| Patent family or example |
Subject matter |
Estimated protection profile |
| U.S. Patent No. 8,278,351 |
Omega-3 carboxylic acid compositions and therapeutic use |
Core composition and use protection, subject to terminal disclaimer, PTA, and Orange Book status |
| U.S. Patent No. 8,318,818 |
Omega-3 free fatty acid pharmaceutical compositions |
Formulation and dosage-form protection |
| U.S. Patent No. 8,865,688 |
Additional omega-3 carboxylic acid composition or treatment claims |
Follow-on protection around formulation or use |
| Related continuation families |
Dosage, administration, and treatment claims |
Potentially later-expiring secondary rights |
Patent expiration dates cannot be inferred solely from the issue date. The analysis must account for the earliest effective nonprovisional filing date, patent-term adjustment, patent-term extension, terminal disclaimers, and any post-grant amendments.
The core estate was generally expected to expire in the late 2020s or around 2030, depending on the specific patent and adjustment calculations. That timing is less commercially important than it would have been for an actively marketed product because AstraZeneca discontinued Epanova development.
What formulations are protected by Epanova patents?
The formulation claims generally focused on:
- Mixtures of EPA and DHA in free fatty acid form.
- Substantially water-insoluble omega-3 ingredients.
- Pharmaceutical compositions suitable for oral administration.
- Dosage forms designed to improve absorption.
- Treatment of elevated triglycerides using defined daily amounts.
The formulation estate could create a barrier for a product that copies the same free-fatty-acid composition and delivery approach. It is less likely to block ordinary fish-oil products, generic omega-3 ethyl ester products, or purified EPA products using materially different chemistry.
What is the Orange Book status of Epanova?
Epanova was listed in the FDA Orange Book during its commercial life under AstraZeneca’s approved NDA. Orange Book relevance depended on whether a listed patent covered the approved drug or an approved method of use.
Because the product was discontinued, the commercial significance of any remaining listing is limited. An Orange Book listing does not by itself establish that a patent is enforceable against every competing omega-3 product. A potential generic applicant would still evaluate:
- Whether the reference drug remains available for ANDA referencing.
- Whether the listed patents remain active.
- Whether a Paragraph IV certification is required.
- Whether the proposed generic uses the same active moiety and dosage form.
- Whether the asserted claims cover the proposed formulation.
FDA approval status and commercial availability are separate issues. A discontinued product can remain in FDA databases even when the sponsor has ceased active promotion.
Which companies challenged or could challenge omega-3-carboxylic-acid patents?
No major, publicly prominent Paragraph IV litigation campaign against Epanova achieved the market visibility associated with blockbuster drugs such as Vascepa or Lovaza. The likely reason is economic. Epanova’s sales were limited, and the opportunity for a generic entrant was less attractive after AstraZeneca stopped commercial development.
Potential challengers would include:
- Generic manufacturers with omega-3 softgel capabilities.
- Specialty pharmaceutical companies targeting severe hypertriglyceridemia.
- Companies developing free-fatty-acid formulations with improved bioavailability.
- Nutraceutical manufacturers seeking prescription-grade positioning.
The principal litigation risk would have been an ANDA challenge to composition or formulation claims. Method-of-use patents could create a separate risk if a generic label included the patented indication. Skinny-label strategies would be possible where the generic omitted protected uses, subject to induced-infringement and labeling issues.
What generic launch risks exist for omega-3-carboxylic acids?
The probability of a commercially meaningful generic launch is moderate to low for Epanova specifically, despite the eventual aging of its patent estate.
A generic entrant would face several constraints:
- Limited branded demand after discontinuation.
- Need to demonstrate pharmaceutical equivalence to a complex free-fatty-acid mixture.
- Potential difficulty matching the reference product’s composition and release characteristics.
- Competition from lower-cost omega-3 ethyl ester products.
- Lack of a cardiovascular-outcomes claim.
- Weak reimbursement economics in a price-sensitive category.
A generic could still be attractive if it uses an abbreviated pathway, captures residual prescriptions, or obtains supply contracts with insurers and wholesalers. The more credible commercial scenario is a niche launch rather than a major market event.
Does omega-3-carboxylic acid have biosimilar risk?
No. Omega-3-carboxylic acids are chemically defined small-molecule active ingredients, not biologics. Biosimilar approval under the Public Health Service Act is not applicable.
Competition would proceed through the small-molecule generic pathway, including an ANDA, or through a 505(b)(2) application for a materially different formulation, dosing regimen, or delivery system.
A 505(b)(2) applicant could seek approval for:
- A modified free-fatty-acid formulation.
- A different capsule or release profile.
- A lower-pill-burden product.
- A formulation with improved tolerability or absorption.
- A new combination with another lipid-lowering agent.
What licensing deals affected the omega-3-carboxylic-acid market?
The defining transaction was AstraZeneca’s acquisition of Omthera Pharmaceuticals in 2013. The deal gave AstraZeneca control of Epanova and Omthera’s omega-3 development platform.
The acquisition thesis included a potential role in dyslipidemia and cardiovascular disease. That thesis weakened after:
- Limited commercial traction following approval.
- Increasing competition from Vascepa.
- Lack of outcomes evidence for mixed EPA/DHA therapy.
- Failure of the STRENGTH trial.
No subsequent high-value licensing transaction restored the asset’s commercial trajectory. The most probable future transaction structure would be an out-licensing or asset sale focused on regional rights, generic development, or formulation technology rather than global branded commercialization.
How strong is the patent estate for omega-3-carboxylic acids?
The patent estate is technically meaningful but commercially weak.
| Strength factor |
Assessment |
| Core composition protection |
Moderate, depending on claim scope and remaining term |
| Formulation protection |
Moderate to strong for closely matching free-fatty-acid products |
| Method-of-use protection |
Limited by the narrow severe-hypertriglyceridemia indication |
| Regulatory exclusivity |
Expired |
| Clinical differentiation |
Weak after STRENGTH failure |
| Generic entry economics |
Limited |
| Licensing value |
Niche and formulation-dependent |
| Litigation value |
Lower than during active commercialization |
The estate could still matter for a company attempting to reproduce the exact Epanova formulation. It is less powerful against products using purified EPA, ethyl ester chemistry, or a different delivery system.
What is the geographic coverage of omega-3-carboxylic-acid rights?
Epanova was developed for multiple markets, but commercial and regulatory outcomes varied by jurisdiction. The relevant rights would include:
- United States composition, formulation, and method patents.
- European patent family members and national validations.
- Japanese and other major-market patent rights where filed.
- Regulatory data and market exclusivity rights tied to local approvals.
- Trademark and know-how rights controlled by AstraZeneca or successor entities.
Patent term and enforceability differ by country. A U.S. patent expiration does not establish freedom to operate in Europe, Japan, Canada, or emerging markets. The practical value of geographic coverage is reduced where the product lacks active commercialization or reimbursement support.
What manufacturing and intellectual-property barriers remain?
The main technical barrier is not synthesis of EPA or DHA. It is consistent manufacture of a pharmaceutical-grade free-fatty-acid mixture with controlled composition, purity, oxidation stability, capsule performance, and batch uniformity.
A competing manufacturer would need to control:
- EPA-to-DHA ratio.
- Oxidative degradation and peroxide levels.
- Heavy metals and environmental contaminants.
- Capsule fill weight and content uniformity.
- Stability under commercial storage conditions.
- Bioequivalence or comparative exposure.
- Supply of purified marine or algal feedstocks.
The intellectual-property barrier is strongest where a product copies the same free-fatty-acid composition and formulation. Manufacturing know-how, analytical methods, supplier qualification, and regulatory documentation may remain more important than patent term for a late entrant.
What is the likely financial trajectory from 2025 onward?
The base-case trajectory is flat to declining because Epanova is no longer positioned as an active growth product. Revenue exposure for AstraZeneca is likely immaterial relative to the company’s oncology, rare-disease, and respiratory portfolios.
Potential value remains in three areas:
- Sale or licensing of regional rights.
- Use of the formulation platform in a new lipid or metabolic product.
- Generic or 505(b)(2) development based on the free-fatty-acid technology.
A relaunch would require a new commercial rationale. Triglyceride reduction alone is unlikely to support premium pricing. A new indication would require clinical evidence, and the failed STRENGTH result would make investors and regulators cautious about broad cardiovascular claims.
Key Takeaways
- Omega-3-carboxylic acids were commercialized as Epanova for severe hypertriglyceridemia.
- AstraZeneca acquired Omthera for approximately $323 million upfront and up to approximately $443 million including milestones.
- Epanova did not become a material disclosed revenue contributor.
- The STRENGTH trial enrolled more than 13,000 patients and stopped for futility after failing to demonstrate cardiovascular benefit.
- Epanova’s mixed EPA/DHA profile lacked the outcomes-based differentiation achieved by purified EPA product Vascepa.
- The patent estate covers free-fatty-acid compositions, formulations, and treatment methods, with core protection generally extending into the late 2020s or around 2030 depending on the patent.
- No biosimilar pathway applies because omega-3-carboxylic acids are small molecules.
- Generic entry is technically feasible but commercially constrained by limited demand and inexpensive competing omega-3 products.
- The asset’s residual value is more likely to arise from licensing, formulation technology, or niche generic development than from renewed branded sales.
FAQs About Omega-3-Carboxylic-Acid Commercial and Patent Risk
Is Epanova still marketed in the United States?
Epanova is no longer an active strategic commercial product for AstraZeneca following discontinuation of development and the failure of the STRENGTH trial.
Can a generic company copy Epanova?
A generic company would need to address the exact active-ingredient composition, dosage form, bioequivalence requirements, and any unexpired Orange Book-listed patents. A 505(b)(2) route may be available for a materially different formulation.
Did Epanova reduce cardiovascular events?
No. The STRENGTH trial did not demonstrate a statistically significant cardiovascular benefit for omega-3 carboxylic acids.
Is Epanova the same as Vascepa?
No. Epanova contained a mixture of omega-3 free fatty acids, principally EPA and DHA. Vascepa contains purified icosapent ethyl, an EPA-only ethyl ester.
Could omega-3-carboxylic acids be relaunched for metabolic disease?
A relaunch would require a commercially differentiated indication, stronger clinical evidence, or a lower-cost formulation. The existing severe-hypertriglyceridemia market is highly competitive and price-sensitive.
References
- U.S. Food and Drug Administration. (2014). Epanova prescribing information. FDA.
- AstraZeneca. (2013). AstraZeneca to acquire Omthera Pharmaceuticals and its novel dyslipidemia treatment Epanova. AstraZeneca press release.
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22.
- Nicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., et al. (2020). Effect of high-dose omega-3 fatty acids vs corn oil on major cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial. JAMA, 324(22), 2268-2280.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- United States Patent and Trademark Office. (n.d.). Patent No. 8,278,351 and related Omthera omega-3 carboxylic acid patent families. USPTO patent records.
